Tekla Capital Management’s Cytokinetics CYTK Stock Holding History

Tekla Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$7.14M	Hold	219,025	–	–	0.28%	70
2023 Q1	$7.71M	Buy	219,025 +143,886	+191%	+$5.87M	0.29%	65
2022 Q4	$3.44M	Hold	75,139	–	–	0.13%	88
2022 Q3	$3.64M	Sell	75,139 -44,759	-37%	-$2.15M	0.15%	93
2022 Q2	$4.71M	Hold	119,898	–	–	0.19%	89
2022 Q1	$4.41M	Buy	119,898 +27,027	+29%	+$960K	0.16%	99
2021 Q4	$4.23M	Buy	+92,871	New	+$3.58M	0.14%	105
2018 Q2	–	Sell	-137,797	Closed	-$992K	–	182
2018 Q1	$992K	Sell	137,797 -212,503	-61%	-$1.82M	0.04%	158
2017 Q4	$2.85M	Buy	+350,300	New	+$3.98M	0.11%	112

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Tekla Capital Management's CYTK Position: Q2 2023 in Review

Tekla Capital Management held its Cytokinetics (CYTK) position steady in Q2 2023 at 219,025 shares worth $7.14M. The position accounts for 0.28% of the portfolio, ranked #70.

Tekla Capital Management first reported a position in CYTK in Q4 2017 and has held it in 9 quarters since. The position peaked at $7.71M in Q1 2023. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Tekla Capital Management held 219,025 shares of Cytokinetics worth $7.14M as of Q2 2023.
Tekla Capital Management left its Cytokinetics share count unchanged in Q2 2023.
Cytokinetics made up 0.28% of Tekla Capital Management's portfolio in Q2 2023, its #70 holding.
Tekla Capital Management first reported a position in Cytokinetics in Q4 2017 and has held it in 9 quarters since.
Tekla Capital Management's Cytokinetics position peaked at $7.71M in Q1 2023.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.